TY - JOUR
T1 - Multimodality Treatment of Gastric Lymphoma
AU - Ikoma, Naruhiko
AU - Badgwell, Brian D.
AU - Mansfield, Paul F.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Gastric lymphoma is rare, accounting for 3% of gastric neoplasms and 10% of lymphomas. Treatment should be stratified based on histologic type, stage, Helicobacter pylori infection, and t(11;18) translocation status. Surgery is no longer a mainstay for treatment and should be reserved for rare situations such as perforation, fistula formation, and severe bleeding. Multimodal treatment, including H pylori eradication, radiation therapy, chemotherapy, and immunotherapy, should be provided as appropriate and can result in excellent outcomes.
AB - Gastric lymphoma is rare, accounting for 3% of gastric neoplasms and 10% of lymphomas. Treatment should be stratified based on histologic type, stage, Helicobacter pylori infection, and t(11;18) translocation status. Surgery is no longer a mainstay for treatment and should be reserved for rare situations such as perforation, fistula formation, and severe bleeding. Multimodal treatment, including H pylori eradication, radiation therapy, chemotherapy, and immunotherapy, should be provided as appropriate and can result in excellent outcomes.
KW - Chemotherapy
KW - Helicobacter pylori infection
KW - Primary gastric lymphoma
KW - Radiation therapy
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=85012897865&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85012897865&partnerID=8YFLogxK
U2 - 10.1016/j.suc.2016.11.012
DO - 10.1016/j.suc.2016.11.012
M3 - Review article
C2 - 28325194
AN - SCOPUS:85012897865
SN - 0039-6109
VL - 97
SP - 405
EP - 420
JO - Surgical Clinics of North America
JF - Surgical Clinics of North America
IS - 2
ER -